Evolus IncNASDAQ:EOLS
- LAST PRICE12.3100
- TODAY'S CHANGE (%)0.1800 (1.4839%)
- Bid / Lots10.3400/ 1
- Ask / Lots12.4800/ 5
- Open / Previous Close12.3400 / 12.1300
- Day Range
- 52 Week Range
- Volume250,431
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EOLS |
|---|---|---|
| 09:32 ET | 3011 | 12.34 |
| 09:34 ET | 1854 | 12.34 |
| 09:36 ET | 800 | 12.4 |
| 09:39 ET | 400 | 12.39 |
| 09:45 ET | 215 | 12.34 |
| 09:50 ET | 738 | 12.36 |
| 09:54 ET | 400 | 12.35 |
| 09:56 ET | 300 | 12.36 |
| 09:57 ET | 800 | 12.34 |
| 10:01 ET | 600 | 12.34 |
| 10:03 ET | 100 | 12.37 |
| 10:06 ET | 400 | 12.35 |
| 10:08 ET | 200 | 12.32 |
| 10:14 ET | 1000 | 12.25 |
| 10:15 ET | 300 | 12.2148 |
| 10:17 ET | 400 | 12.21 |
| 10:19 ET | 100 | 12.19 |
| 10:21 ET | 300 | 12.18 |
| 10:26 ET | 500 | 12.2 |
| 10:28 ET | 100 | 12.2 |
| 10:30 ET | 300 | 12.13 |
| 10:32 ET | 200 | 12.09 |
| 10:33 ET | 200 | 12.05 |
| 10:35 ET | 209 | 12.065 |
| 10:37 ET | 200 | 12.062 |
| 10:39 ET | 1500 | 12.12 |
| 10:42 ET | 500 | 12.15 |
| 10:44 ET | 1005 | 12.15 |
| 10:48 ET | 200 | 12.145 |
| 10:50 ET | 300 | 12.14 |
| 10:51 ET | 615 | 12.11 |
| 10:53 ET | 300 | 12.12 |
| 10:55 ET | 100 | 12.1101 |
| 11:02 ET | 600 | 12.14 |
| 11:04 ET | 100 | 12.125 |
| 11:06 ET | 200 | 12.13 |
| 11:08 ET | 300 | 12.11 |
| 11:09 ET | 400 | 12.11 |
| 11:13 ET | 400 | 12.13 |
| 11:18 ET | 232 | 12.09 |
| 11:20 ET | 563 | 12.07 |
| 11:22 ET | 100 | 12.06 |
| 11:26 ET | 500 | 12.09 |
| 11:29 ET | 300 | 12.11 |
| 11:33 ET | 648 | 12.12 |
| 11:36 ET | 100 | 12.1 |
| 11:38 ET | 500 | 12.13 |
| 11:45 ET | 400 | 12.15 |
| 11:47 ET | 100 | 12.13 |
| 11:49 ET | 600 | 12.15 |
| 11:56 ET | 1402 | 12.13 |
| 12:00 ET | 612 | 12.17 |
| 12:02 ET | 100 | 12.175 |
| 12:03 ET | 400 | 12.18 |
| 12:05 ET | 162 | 12.19 |
| 12:12 ET | 810 | 12.2 |
| 12:14 ET | 1400 | 12.155 |
| 12:16 ET | 100 | 12.16 |
| 12:21 ET | 200 | 12.14 |
| 12:27 ET | 444 | 12.14 |
| 12:30 ET | 100 | 12.13 |
| 12:32 ET | 300 | 12.14 |
| 12:34 ET | 900 | 12.13 |
| 12:36 ET | 510 | 12.14 |
| 12:38 ET | 200 | 12.14 |
| 12:41 ET | 100 | 12.12 |
| 12:43 ET | 816 | 12.16 |
| 12:50 ET | 505 | 12.15 |
| 12:52 ET | 100 | 12.12 |
| 12:54 ET | 156 | 12.12 |
| 12:56 ET | 3405 | 12.12 |
| 12:57 ET | 1010 | 12.105 |
| 12:59 ET | 1600 | 12.15 |
| 01:06 ET | 100 | 12.17 |
| 01:08 ET | 400 | 12.17 |
| 01:10 ET | 200 | 12.175 |
| 01:12 ET | 100 | 12.185 |
| 01:14 ET | 400 | 12.195 |
| 01:15 ET | 700 | 12.19 |
| 01:24 ET | 300 | 12.18 |
| 01:30 ET | 550 | 12.2 |
| 01:33 ET | 677 | 12.19 |
| 01:35 ET | 100 | 12.18 |
| 01:37 ET | 1850 | 12.14 |
| 01:42 ET | 920 | 12.17 |
| 01:46 ET | 900 | 12.2 |
| 01:48 ET | 100 | 12.2 |
| 01:51 ET | 100 | 12.18 |
| 01:55 ET | 100 | 12.19 |
| 01:57 ET | 100 | 12.19 |
| 02:00 ET | 200 | 12.19 |
| 02:02 ET | 105 | 12.19 |
| 02:04 ET | 912 | 12.23 |
| 02:06 ET | 227 | 12.22 |
| 02:08 ET | 300 | 12.21 |
| 02:13 ET | 100 | 12.21 |
| 02:15 ET | 249 | 12.22 |
| 02:18 ET | 403 | 12.23 |
| 02:20 ET | 600 | 12.22 |
| 02:22 ET | 213 | 12.22 |
| 02:26 ET | 500 | 12.25 |
| 02:27 ET | 595 | 12.245 |
| 02:29 ET | 185 | 12.24 |
| 02:31 ET | 100 | 12.23 |
| 02:33 ET | 313 | 12.23 |
| 02:36 ET | 100 | 12.22 |
| 02:40 ET | 519 | 12.24 |
| 02:42 ET | 200 | 12.24 |
| 02:45 ET | 300 | 12.26 |
| 02:47 ET | 100 | 12.25 |
| 02:51 ET | 1055 | 12.25 |
| 02:56 ET | 409 | 12.26 |
| 02:58 ET | 700 | 12.27 |
| 03:00 ET | 799 | 12.26 |
| 03:02 ET | 400 | 12.25 |
| 03:05 ET | 100 | 12.22 |
| 03:07 ET | 700 | 12.24 |
| 03:09 ET | 200 | 12.25 |
| 03:12 ET | 600 | 12.27 |
| 03:14 ET | 400 | 12.28 |
| 03:16 ET | 927 | 12.27 |
| 03:23 ET | 200 | 12.28 |
| 03:25 ET | 335 | 12.29 |
| 03:30 ET | 577 | 12.27 |
| 03:32 ET | 2123 | 12.3 |
| 03:34 ET | 100 | 12.28 |
| 03:36 ET | 100 | 12.27 |
| 03:38 ET | 100 | 12.28 |
| 03:39 ET | 900 | 12.29 |
| 03:41 ET | 1908 | 12.29 |
| 03:43 ET | 100 | 12.275 |
| 03:45 ET | 1426 | 12.3 |
| 03:48 ET | 321 | 12.3 |
| 03:50 ET | 1239 | 12.28 |
| 03:52 ET | 2048 | 12.31 |
| 03:54 ET | 1967 | 12.27 |
| 03:56 ET | 1509 | 12.28 |
| 03:57 ET | 3958 | 12.29 |
| 03:59 ET | 6164 | 12.31 |
Yesterday
Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference, from 8:00AM ET on Thursday Jul 25, 2024 by Dow Jones
8:00AM ET on Thursday Jul 25, 2024 by Dow Jones
Jul 17, 2024
Press Release: Evolus to Report Second Quarter Financial Results on July 31, 2024, from 8:04AM ET on Wednesday Jul 17, 2024 by Dow Jones
8:04AM ET on Wednesday Jul 17, 2024 by Dow JonesEvolus to Report Second Quarter Financial Results on July 31, 2024, from 8:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
8:00AM ET on Wednesday Jul 17, 2024 by Dow Jones
Jul 1, 2024
*DJ Evolus Appoints Albert G. White to Bd of Directors >EOLS, from 8:01AM ET on Monday Jul 01, 2024 by Dow Jones
8:01AM ET on Monday Jul 01, 2024 by Dow JonesEvolus Announces Appointment of Albert G. White III to Board of Directors, from 8:00AM ET on Monday Jul 01, 2024 by Dow Jones
8:00AM ET on Monday Jul 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Evolus Inc | 759.5M | -11.8x | --- |
SIGA Technologies Inc | 711.9M | 9.6x | -28.78% |
Harrow Inc | 857.3M | -26.9x | --- |
Xeris Biopharma Holdings Inc | 378.8M | -5.6x | --- |
Takeda Pharmaceutical Co Ltd | 43.8B | 46.5x | -8.01% |
LifeVantage Corp | 88.9M | 28.7x | -16.83% |
Company Information
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Contact Information
- Headquarters
- 520 Newport Center Dr Ste 1200NEWPORT BEACH, CA, United States 92660-7022
- Phone
- 949-284-4555
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Vikram Malik
- President, Chief Executive Officer, Director
- David Moatazedi
- Chief Financial Officer
- Sandra Beaver
- Chief Marketing Officer
- Tomoko Yamagishi-Dressler
- Chief Medical Officer, Head - Research and Development
- Rui Avelar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $759.5M |
|---|---|
Revenue (TTM) | $219.7M |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-1.05 |
Book Value | $-0.36 |
P/E Ratio | -11.8x |
Price/Sales (TTM) | 3.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -20.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
